Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.

Increased extracellular matrix (ECM) deposition is a characteristic observed in many solid tumors. Increased levels of one ECM component-namely, hyaluronan (HA)-leads to reduced elasticity of tumor tissue and increased interstitial fluid pressure. Multiple initial reports showed that the addition of hyaluronidase (HYAL) to chemotherapeutic regimens could greatly improve efficacy. Unfortunately, the bovine HYAL used in those studies was limited therapeutically by immunologic responses to treatment. Newly developed recombinant human HYAL has recently been introduced into clinical trials. In this article, we describe the role of HA in cancer, methods of targeting HA, and clinical studies performed to date, and we propose that targeting HA could now be an effective treatment option for patients with many different types of solid tumors.

[1]  I. Kakizaki,et al.  A hyaluronan synthase suppressor, 4‐methylumbelliferone, inhibits liver metastasis of melanoma cells , 2005, FEBS letters.

[2]  A. Buschauer,et al.  Hyaluronidase pretreatment produces selective melphalan enrichment in malignant melanoma implanted in nude mice , 1996, Cancer Chemotherapy and Pharmacology.

[3]  S. Wieser,et al.  Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. , 1998, Cancer letters.

[4]  J. Sleeman,et al.  Dermal hyaluronan is rapidly reduced by topical treatment with glucocorticoids. , 2010, The Journal of investigative dermatology.

[5]  P. O'Connor,et al.  Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.

[6]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[7]  B. Delpech,et al.  Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: Comparison between invasive and non‐invasive areas , 1992, International journal of cancer.

[8]  D. V. Von Hoff,et al.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.

[9]  T. Ohnuma,et al.  Effects of hyaluronidase on doxorubicin penetration into squamous carcinoma multicellular tumor spheroids and its cell lethality , 2005, Journal of Cancer Research and Clinical Oncology.

[10]  U. Maier,et al.  Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. , 1989, The Journal of urology.

[11]  I. Slavc,et al.  Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. , 1998, Cancer letters.

[12]  V. Lokeshwar,et al.  Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. , 2010, Cancer research.

[13]  L. Sakr,et al.  The impact of extracellular matrix on the chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. , 1998, Cancer letters.

[14]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[15]  K. Smith,et al.  Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). , 1997, Journal of the American Academy of Dermatology.

[16]  A. Maitra,et al.  Abstract C246: nab®‐paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer models , 2009 .

[17]  D. Kennard,et al.  Assessment and Implication of the Allergic Sensitivity to a Single Dose of Recombinant Human Hyaluronidase Injection: A Double‐blind, Placebo‐controlled Clinical Trial , 2007, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

[18]  G. Bernhardt,et al.  Hyaluronidase enhances the activity of Adriamycin in breast cancer models in vitro and in vivo , 2005, Journal of Cancer Research and Clinical Oncology.